Form 4: MAIA Director Boosts Stake with Stock and Options Buy

MAIA Biotechnology Director Steven M. Chaouki acquired 40,849 shares of common stock and 40,849 stock options on December 22, 2025, increasing his direct beneficial ownership.

Summary

• Director Steven M. Chaouki purchased 40,849 shares of MAIA Biotechnology, Inc. common stock at a price of $1.224 per share.
• He also acquired 40,849 stock options with an exercise price of $1.36 per option.
• The common stock and options were purchased on December 22, 2025, pursuant to a Securities Purchase Agreement and issued under the company's 2021 Equity Incentive Plan.
• Following these transactions, Mr. Chaouki directly beneficially owns 151,873 shares of common stock and 40,849 stock options.
• The stock options become exercisable on June 22, 2026, and expire on December 22, 2028.

Sentiment

Score: 8

Explanation: The direct purchase of common stock and stock options by a director is a strong positive signal, indicating management's belief in the company's future value and aligning their interests with shareholders.

Positives

• Director Steven M. Chaouki increased his direct beneficial ownership in the company, signaling confidence in MAIA Biotechnology's future prospects.
• The acquisition of both common stock and stock options demonstrates a dual commitment to both immediate equity and future potential upside.

Future Outlook

NA

Industry Context

This insider purchase by a director of MAIA Biotechnology, a company in the biotechnology sector, suggests internal confidence in the company's drug development pipeline or strategic direction. Such transactions are often closely watched by investors for signals regarding future performance, especially in a sector characterized by high risk and high reward.

Related Party Transactions

• Director Steven M. Chaouki's acquisition of common stock and stock options from MAIA Biotechnology, Inc. constitutes a related party transaction, executed pursuant to a Securities Purchase Agreement and the company's 2021 Equity Incentive Plan.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign of confidence, potentially leading to increased investor interest and a more aligned management-shareholder interest.
• Employees might perceive this as a sign of stability and positive internal outlook for the company's future.

Key Dates

Recommendation

The significant insider buying by a director, Steven M. Chaouki, who acquired both common stock and stock options, signals strong conviction in MAIA Biotechnology's future performance and valuation. Insider purchases are often interpreted as a bullish indicator, suggesting that those with the most intimate knowledge of the company believe the stock is undervalued or poised for growth. This action aligns management's interests more closely with shareholders and could precede positive operational developments.

Keywords

MAIA Biotechnology, MAIA, Insider Trading, Director Purchase, Stock Options, Equity Incentive Plan, Biotechnology, SEC Form 4